Novare Capital Management Boosted By $1.89 Million Its Golub Capital Bdc (GBDC) Position; Myriad Genetics (MYGN)’s Sentiment Is 1.37

April 20, 2018 - By Marie Mckinney

Novare Capital Management Llc increased Golub Capital Bdc (GBDC) stake by 350.58% reported in 2017Q4 SEC filing. Novare Capital Management Llc acquired 105,000 shares as Golub Capital Bdc (GBDC)’s stock declined 2.87%. The Novare Capital Management Llc holds 134,950 shares with $2.46M value, up from 29,950 last quarter. Golub Capital Bdc now has $1.07 billion valuation. The stock decreased 0.17% or $0.03 during the last trading session, reaching $17.91. About 26,729 shares traded. Golub Capital BDC, Inc. (NASDAQ:GBDC) has declined 6.66% since April 20, 2017 and is downtrending. It has underperformed by 18.21% the S&P500.

Myriad Genetics Inc (MYGN) investors sentiment increased to 1.37 in 2017 Q4. It’s up 0.51, from 0.86 in 2017Q3. The ratio is better, as 118 active investment managers increased and started new positions, while 86 cut down and sold stock positions in Myriad Genetics Inc. The active investment managers in our database now possess: 71.43 million shares, down from 71.79 million shares in 2017Q3. Also, the number of active investment managers holding Myriad Genetics Inc in top ten positions decreased from 4 to 1 for a decrease of 3. Sold All: 19 Reduced: 67 Increased: 72 New Position: 46.

Since February 12, 2018, it had 4 buys, and 0 sales for $994,166 activity. On Friday, February 23 the insider WEBSTER WILLIAM M IV bought $362,000.

Among 5 analysts covering Golub Capital BDC (NASDAQ:GBDC), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Golub Capital BDC had 10 analyst reports since August 24, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, February 12 by National Securities. On Tuesday, September 20 the stock rating was initiated by Janney Capital with “Neutral”. Cantor Fitzgerald upgraded it to “Buy” rating and $18.50 target in Tuesday, September 1 report. The company was maintained on Friday, May 13 by Keefe Bruyette & Woods. On Friday, February 10 the stock rating was downgraded by Raymond James to “Mkt Perform”. National Securities initiated Golub Capital BDC, Inc. (NASDAQ:GBDC) on Thursday, November 3 with “Neutral” rating. The firm has “Hold” rating by Keefe Bruyette & Woods given on Sunday, July 23. The stock of Golub Capital BDC, Inc. (NASDAQ:GBDC) earned “Hold” rating by Keefe Bruyette & Woods on Thursday, October 5. As per Monday, March 27, the company rating was upgraded by Raymond James. The firm has “Market Perform” rating by Wells Fargo given on Monday, August 24.

Investors sentiment decreased to 0.92 in 2017 Q4. Its down 0.48, from 1.4 in 2017Q3. It is negative, as 11 investors sold GBDC shares while 41 reduced holdings. 10 funds opened positions while 38 raised stakes. 20.38 million shares or 7.82% less from 22.10 million shares in 2017Q3 were reported. New York-based Blackrock Inc has invested 0% in Golub Capital BDC, Inc. (NASDAQ:GBDC). Advsr Cap Management Ltd Co stated it has 279,563 shares. Raymond James Fin Serv accumulated 16,565 shares. Pekin Singer Strauss Asset Mngmt Il accumulated 22,288 shares. Ubs Asset Management Americas holds 0% of its portfolio in Golub Capital BDC, Inc. (NASDAQ:GBDC) for 3,391 shares. Sumitomo Mitsui Asset Mgmt reported 262,376 shares. Williams Jones & Associates Limited Com has 0.02% invested in Golub Capital BDC, Inc. (NASDAQ:GBDC). Evercore Wealth Limited Liability invested 0.01% in Golub Capital BDC, Inc. (NASDAQ:GBDC). Edgemoor Inv Advisors Inc holds 0.35% of its portfolio in Golub Capital BDC, Inc. (NASDAQ:GBDC) for 154,975 shares. Fort Washington Advsrs Oh holds 0.02% or 93,267 shares in its portfolio. Moreover, Cullen Frost Bankers Inc has 0.01% invested in Golub Capital BDC, Inc. (NASDAQ:GBDC) for 25,546 shares. New York-based Clearbridge Invs Ltd Liability has invested 0.01% in Golub Capital BDC, Inc. (NASDAQ:GBDC). First Republic Inv Mngmt invested in 0.03% or 247,877 shares. Cardinal Limited Liability Corporation Ct owns 585,261 shares. Atlantic Tru Limited Liability has 139,325 shares for 0.01% of their portfolio.

Novare Capital Management Llc decreased Powershares High Dividend (PEY) stake by 26,130 shares to 65,950 valued at $1.18M in 2017Q4. It also reduced Powershs Rafi Us 1000 (PRF) stake by 15,104 shares and now owns 86,978 shares. Paypal Holdings was reduced too.

The stock decreased 0.28% or $0.08 during the last trading session, reaching $28.96. About 79,618 shares traded. Myriad Genetics, Inc. (MYGN) has risen 52.68% since April 20, 2017 and is uptrending. It has outperformed by 41.13% the S&P500.

Since January 1, 0001, it had 0 buys, and 7 selling transactions for $5.48 million activity.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on May, 1. They expect $0.27 EPS, 0.00% or $0.00 from last year’s $0.27 per share. MYGN’s profit will be $18.86M for 26.81 P/E if the $0.27 EPS becomes a reality. After $0.31 actual EPS reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts -12.90% negative EPS growth.

Ratings analysis reveals 0 of Myriad Genetics’s analysts are positive. Out of 2 Wall Street analysts rating Myriad Genetics, 0 give it “Buy”, 2 “Sell” rating, while 0 recommend “Hold”. MYGN was included in 2 notes of analysts from October 10, 2016. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Sell” rating given on Wednesday, January 18 by Deutsche Bank. Ladenburg Thalmann downgraded the stock to “Sell” rating in Monday, October 10 report.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.02 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 15.54 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

Tieton Capital Management Llc holds 3.67% of its portfolio in Myriad Genetics, Inc. for 124,338 shares. S&T Bank Pa owns 476,156 shares or 2.77% of their US portfolio. Moreover, Camber Capital Management Llc has 2.52% invested in the company for 1.50 million shares. The California-based Taylor Frigon Capital Management Llc has invested 1.22% in the stock. Aimz Investment Advisors Llc, a California-based fund reported 43,785 shares.

By1 Marie Mckinney